In the two decades between the initial discovery of the clinical benefit of atRA in APL and the mechanistic dissection of the PML-RARα fusion oncoprotein, more than 100,000 patients were enrolled in randomized controlled trials testing various retinoid pathway agonists to prevent cancer. The gene discussed is PML; the disease is cancer.